Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
Key Highlights
- ➤$9.3 million annualized operating-cost savings planned
- ➤$4.3 million reinvestment leaves $5.0 million net annualized reduction
- ➤Approximately 40 positions, or 6% of employees, will be eliminated
- ➤Clinical Genomics revenue will decline as Mesa focuses on profitability
- ➤Fiscal 2027 guidance reflecting the plan arrives November 9, 2026
Expert Statements
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“Mesa is a set of durable, regulation-embedded franchises with real and growing earnings power, and fixable execution problems we have already begun to fix”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“My focus is disciplined execution and consistent, profitable growth across our four divisions.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“As I said on our first quarter call, we are managing Clinical Genomics deliberately, with full attention to its cost structure and returns. Following the business reviews I have completed over my first six months, we are managing it for profitability, not for scale. These were difficult decisions, and we approached each one with care and respect for our team members. At the same time, we have a responsibility to position the business for sustainable, profitable growth.”
Siddhartha Kadia, President and Chief Executive Officer of Mesa Laboratories
“This is not a broad cost reduction. It follows a decision about which customers Clinical Genomics is built to serve. We are focusing Clinical Genomics on pharmacogenomics and oncology, on customer accounts that use the instrument at scale, and we are sizing the organization for that. This is not a decision to pull back from specific regions; if an account uses the instrument at scale, we want to serve it wherever it is. Revenue will be lower as a result, but we expect profitability to be meaningfully higher as the cost comes out, and gross profit percentage to improve, because the revenue we are stepping away from is the lowest-margin revenue we have in Clinical Genomics. We are also redirecting resources to accelerate standard product launches, the fastest-growing part of the Clinical Genomics portfolio. Our obligation is to make every business in this portfolio earn its cost of capital, and we will report against that standard.”
The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia
LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million. The Savings Plan consists of a global restructuring program (the "Restructuring Program"), a reduction in our San Diego, California facility footprint and reduced third-party spending. We plan to reinvest approximately $4.3 million of the savings into the business to drive profitable growth, for a net annualized cost reduction of approximately $5.0 million.
Get started
Create a free account to read the full story.